Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 2
1984 1
1985 3
1986 3
1987 3
1988 6
1989 6
1990 8
1991 4
1992 5
1993 11
1994 11
1995 12
1996 13
1997 12
1998 27
1999 21
2000 31
2001 37
2002 27
2003 40
2004 38
2005 50
2006 58
2007 79
2008 53
2009 62
2010 67
2011 63
2012 74
2013 98
2014 93
2015 83
2016 115
2017 133
2018 141
2019 129
2020 136
2021 152
2022 148
2023 140
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

1,951 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
METHODS: This phase 3, double-blind, randomised, placebo-controlled trial was conducted in seven countries. Adults (aged 18 years) with a body-mass index (BMI) of 27 kg/m(2) or higher and glycated haemoglobin (HbA(1c)) of 7-10% (53-86 mmo …
METHODS: This phase 3, double-blind, randomised, placebo-controlled trial was conducted in seven countrie …
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Kadowaki T, et al. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. Lancet Diabetes Endocrinol. 2022. PMID: 35131037 Clinical Trial.
Differences exist between Asian and non-Asian populations in terms of body composition and definitions of obesity. In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus pla …
Differences exist between Asian and non-Asian populations in terms of body composition and definitions of obesity. In t …
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Greenway FL, et al. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Lancet. 2010. PMID: 20673995 Clinical Trial.
The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants. METHODS: Men and women aged 18-65 years who had a body-mass index (BMI) of 30-45 kg/m(2) and uncomplicated …
The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and …
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Wadden TA, et al. Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15. Nat Med. 2023. PMID: 37840095 Free PMC article. Clinical Trial.
This double-blind, placebo-controlled trial randomized (1:1) adults with body mass index 30 or 27 kg/m(2) and at least one obesity-related complication (excluding diabetes), who achieved 5.0% weight reduction after a 12-week intens …
This double-blind, placebo-controlled trial randomized (1:1) adults with body mass index 30 or 27 …
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Wadden TA, et al. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726. Obesity (Silver Spring). 2020. PMID: 32090517 Free PMC article. Clinical Trial.
The present multisite study provides the first evaluation, in primary care, of the effect of the Centers for Medicare and Medicaid Services-based IBT benefit, delivered alone (with placebo) or in combination with liraglutide 3.0 mg. METHODS: The Satiety and Clinical Adipos …
The present multisite study provides the first evaluation, in primary care, of the effect of the Centers for Medicare and Medicaid Se …
Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and the Gut Microbiota in Humans: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Mo SJ, Lee K, Hong HJ, Hong DK, Jung SH, Park SD, Shim JJ, Lee JL. Mo SJ, et al. Nutrients. 2022 Jun 15;14(12):2484. doi: 10.3390/nu14122484. Nutrients. 2022. PMID: 35745214 Free PMC article. Clinical Trial.
Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and human health. ...A randomized, double-blind, placebo-controlled study was conducted on 72 individuals with …
Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and hu …
Metagenomics analysis of gut microbiota in response to diet intervention and gestational diabetes in overweight and obese women: a randomised, double-blind, placebo-controlled clinical trial.
Mokkala K, Paulin N, Houttu N, Koivuniemi E, Pellonperä O, Khan S, Pietilä S, Tertti K, Elo LL, Laitinen K. Mokkala K, et al. Gut. 2021 Feb;70(2):309-318. doi: 10.1136/gutjnl-2020-321643. Epub 2020 Aug 24. Gut. 2021. PMID: 32839200 Free article. Clinical Trial.
DESIGN: The gut microbiota of 270 overweight/obese women participating in a mother-infant clinical study were analysed with metagenomics approach in early (mean gestational weeks 13.9) and late (gestational weeks 35.2) pregnancy. ...CONCLUSIONS: The specific …
DESIGN: The gut microbiota of 270 overweight/obese women participating in a mother-infant clinical study were analysed …
Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial.
Park SH, Huh TL, Kim SY, Oh MR, Tirupathi Pichiah PB, Chae SW, Cha YS. Park SH, et al. Obesity (Silver Spring). 2014 Jan;22(1):63-71. doi: 10.1002/oby.20539. Epub 2013 Sep 5. Obesity (Silver Spring). 2014. PMID: 23804546 Free article. Clinical Trial.
OBJECTIVE: The effects of actiponin was investigated, a heat-processed Gynostemma pentaphyllum extract, on body weight, fat loss, and metabolic markers of Korean participants in a 12-week, randomized, double-blind, placebo-controlled …
OBJECTIVE: The effects of actiponin was investigated, a heat-processed Gynostemma pentaphyllum extract, on body weight, fat lo …
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. le Roux CW, et al. Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5. Lancet Diabetes Endocrinol. 2024. PMID: 38330987 Clinical Trial.
BACKGROUND: Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, tolerability, and efficacy of glucagon receptor-GLP- …
BACKGROUND: Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to imp …
Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women.
Sanchez M, Darimont C, Drapeau V, Emady-Azar S, Lepage M, Rezzonico E, Ngom-Bru C, Berger B, Philippe L, Ammon-Zuffrey C, Leone P, Chevrier G, St-Amand E, Marette A, Doré J, Tremblay A. Sanchez M, et al. Br J Nutr. 2014 Apr 28;111(8):1507-19. doi: 10.1017/S0007114513003875. Epub 2013 Dec 3. Br J Nutr. 2014. PMID: 24299712 Free article. Clinical Trial.
The present study investigated the impact of a Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation on weight loss and maintenance in obese men and women over 24 weeks. In a double-blind, placebo-controlled, randomised trial, …
The present study investigated the impact of a Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation on weight loss and maintenan …
1,951 results